Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Rating of “Reduce” from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has earned a consensus recommendation of “Reduce” from the nine research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company.

Several research analysts recently issued reports on BAYRY shares. Wolfe Research downgraded Bayer Aktiengesellschaft from an “outperform” rating to a “peer perform” rating in a research report on Tuesday, January 30th. Citigroup restated a “neutral” rating on shares of Bayer Aktiengesellschaft in a research report on Thursday, February 29th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Bayer Aktiengesellschaft in a research report on Thursday, March 7th.

Bayer Aktiengesellschaft Stock Performance

BAYRY opened at $7.68 on Thursday. The stock’s 50 day simple moving average is $7.36 and its 200 day simple moving average is $8.49. The stock has a market cap of $30.18 billion, a P/E ratio of -9.37 and a beta of 1.11. Bayer Aktiengesellschaft has a 1-year low of $6.96 and a 1-year high of $16.15. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.27 and a quick ratio of 0.80.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Tuesday, March 5th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.12. Bayer Aktiengesellschaft had a positive return on equity of 17.27% and a negative net margin of 6.31%. The business had revenue of $12.77 billion during the quarter. As a group, equities analysts anticipate that Bayer Aktiengesellschaft will post 1.36 EPS for the current fiscal year.

Bayer Aktiengesellschaft Cuts Dividend

The firm also recently declared a dividend, which will be paid on Monday, May 13th. Investors of record on Tuesday, April 30th will be issued a $0.0191 dividend. The ex-dividend date is Monday, April 29th. Bayer Aktiengesellschaft’s payout ratio is -2.44%.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.